Φορτώνει......
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Sorafenib is an oral kinase inhibitor that enhances survival in patients affected by advanced hepatocellular carcinoma (HCC). According to the results of two registrative trials, this drug represents a gold quality standard in the first line treatment of advanced HCC. Recently, lenvatinib showed sim...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Medicina (Kaunas) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
MDPI
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6843290/ https://ncbi.nlm.nih.gov/pubmed/31640191 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55100707 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|